Gioia Riboni-Verri

Gioia Riboni-Verri

Auto-generated profile, based on publicly available information

Gioia Riboni-Verri

Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025 in Trials
Verified
Journal Article
Open access
GRGioia Riboni-Verri
Gioia Riboni-Verri
CMChris McMurran
Chris McMurran
TMTrisha Mukherjee
Trisha Mukherjee
CDCyrus Daruwalla
Cyrus Daruwalla
JHJonathon Holland
Jonathon Holland
NCNick G Cunniffe
Nick G Cunniffe
Background: In multiple sclerosis (MS), progressive disability occurs following degeneration of demyelinated axons. A tractable approach to delay, prevent or reverse disability progression is through enhancement of endogenous remyelination. Clinical trials have deployed drugs, such as clemastine, to target the rate-limiting step in this process: differentiation of oligodendrocyte progenitor cells (OPCs). Preclinical research has shown that metformin can reverse an age-associated deficit in the responsiveness of OPCs to pro-differentiation factors. The purpose of the Cambridge Centre for Myelin Repair trial Two (CCMR Two) is to evaluate the efficacy of the combination of metformin and clemastine to promote remyelination in people with MS. Methods: Participants with relapsing-remitting MS (RRMS) will be randomised 1:1 to the combination of metformin and clemastine or matched placebos and followed for 24 weeks of treatment. All participants must be stable on a disease-modifying therapy and have evidence of chronic stable optic neuropathy in at least one eye (defined by P100 latency of the visual evoked potential (VEP) ≥ 118 ms, and the absence of a history of acute optic neuritis in the preceding 2 years). The primary outcome measure will be the change in the P100 latency of the full-field VEP between baseline and week 26. It is planned to recruit a total of 70 participants. This will have 80% power to detect a reduction of 3 ms in VEP P100 latency between the two treatment groups. Secondary outcome measures will examine the change in multifocal VEP and the change in lesional magnetisation transfer ratio (MTR) for lesions stratified by location and tissue-specific cohort baseline lesional MTR values. Discussion: We set out the trial design, the rationale for participant and outcome measure selection, and the pre-specified analyses. With this trial, we expect to be able to detect the structural and functional consequences of remyelination within a sample size feasible for our single-centre trial. Trial registration: ClinicalTrials.gov NCT05131828, prior to participant enrolment.

19 February 2024 in BMJ Neurology Open
Verified
Journal Article
Open access
PDF file
GRGioia Riboni-Verri
Gioia Riboni-Verri
BCBenson S Chen
Benson S Chen
CMChristopher E McMurran
Christopher E McMurran
GHGregory J Halliwell
Gregory J Halliwell
JBJ William L Brown
J William L Brown
NCNick G Cunniffe
Nick G Cunniffe
One of the most promising approaches to delay, prevent or reverse disability progression in multiple sclerosis (MS) is to enhance endogenous remyelination and limit axonal degeneration. In clinical trials of remyelinating drugs, there is a need for reliable, sensitive and clinically relevant outcome measures. The visual pathway, which is frequently affected by MS, provides a unique model system to evaluate remyelination of acute and chronic MS lesions in vivo and non-invasively. In this review, we discuss the different measures that have been used and scrutinise visual outcome measure selection in current and future remyelination trials.

27 July 2025 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Open access
GRGioia Riboni-Verri
Gioia Riboni-Verri
CMChris McMurran
Chris McMurran
JKJens Kuhle
Jens Kuhle
LHLisa Hofer
Lisa Hofer
ACAlasdair Coles
Alasdair Coles
NCNick G Cunniffe
Nick G Cunniffe
Remyelination offers a potential neuroprotective strategy in multiple sclerosis (MS). In the Cambridge Centre of Myelin Repair One (CCMR-One) trial, bexarotene, an RXR agonist, promoted remyelination in people with MS, evidenced through a reduction in the latency of the full-field visual evoked potential (VEP). However, it remained uncertain whether bexarotene additionally promoted neuroprotection. We conducted a sub-study of the Cambridge-based (n = 31) participants of the CCMR-One trial. Participants were aged 18-50 years, had baseline EDSS 0-6.0 and had been stable on dimethyl fumarate for at least 6 months. Consenting participants contributed serum samples at baseline and month 6, which were analysed for neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP), total Tau protein (Tau), and C-terminal hydrolase L1 (UCHL1). The change in serum biomarker values and their associations with changes in VEP latency were assessed using linear models adjusted for age, sex, EDSS, disease duration and baseline biomarker levels. 27 participants consented to provide blood samples (15 bexarotene, 12 placebo). There were no significant differences in biomarker change between these groups. However, a significant interaction was observed between treatment group and sNfL change (p = 0.001) among those with prolonged baseline VEP latency (≥118 ms). In the bexarotene group, latency improvement was associated with a reduction in sNfL (β = 23.4 ms per log[pg/mL] decrease; 95 % CI 11.1 to 36.2); this relationship was not seen in the placebo group. Bexarotene-induced remyelination was associated with reduced sNfL in individuals with prior demyelination, suggesting a potential neuroprotective effect.

19 August 2025 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
GRGioia Riboni-Verri
Gioia Riboni-Verri
RGRiddhima Gautam
Riddhima Gautam
BCBenson Chen
Benson Chen
NCNick G Cunniffe
Nick G Cunniffe
Background: Aberrant myelination of the retinal nerve fibre layer (RNFL) can follow lamina cribrosa damage. Such cases may provide insight into how increased myelin affects the visual evoked potential (VEP), a key outcome in remyelination trials. Objective: We present the case of a myelinated RNFL in a patient with relapsing-remitting multiple sclerosis (RRMS) with accompanying electrophysiology. Methods: Visual assessments used a VisionSearch Plus, Heidelberg Spectralis optical coherence tomography, and Topcon fundus camera. Results: Full-field visual evoked potential (FF-VEP) peak time latency was abnormally short, 90 ms. Conclusion: This is the first known case report of a myelinated RNFL with electrophysiology, which supports the assertion that reductions in VEP latency correlate with myelination.